tanshinone ii a has been researched along with bicalutamide in 2 studies
| Studies (tanshinone ii a) | Trials (tanshinone ii a) | Recent Studies (post-2010) (tanshinone ii a) | Studies (bicalutamide) | Trials (bicalutamide) | Recent Studies (post-2010) (bicalutamide) |
|---|---|---|---|---|---|
| 61 | 0 | 41 | 1,313 | 212 | 541 |
| Protein | Taxonomy | tanshinone ii a (IC50) | bicalutamide (IC50) |
|---|---|---|---|
| Progesterone receptor | Oryctolagus cuniculus (rabbit) | 5.6 | |
| Progesterone receptor | Homo sapiens (human) | 1.819 | |
| Androgen receptor | Homo sapiens (human) | 0.404 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 0.7168 | |
| Androgen receptor | Mus musculus (house mouse) | 1.835 | |
| Testosterone 17-beta-dehydrogenase 3 | Homo sapiens (human) | 0.12 | |
| Progesterone receptor | Rattus norvegicus (Norway rat) | 0.89 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geng, G; Liu, W; Sauriol, F; Shi, Q; Wu, JH; Zhou, J | 1 |
| Li, F; Song, L; Tang, L; Tian, F; Wang, Z; Yang, J; Yu, Z | 1 |
2 other study(ies) available for tanshinone ii a and bicalutamide
| Article | Year |
|---|---|
Antiandrogenic, maspin induction, and antiprostate cancer activities of tanshinone IIA and its novel derivatives with modification in ring A.
Topics: Abietanes; Androgen Antagonists; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Humans; Male; Mutation; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Serpins; Structure-Activity Relationship; Transcriptional Activation | 2012 |
Clinical research of Tashinone IIA combined with endocrine therapy in treating advanced-stage prostate cancer.
Topics: Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Hemoglobins; Humans; Leuprolide; Male; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Tosyl Compounds; Treatment Outcome | 2014 |